Summary
Jon Krell is a Senior Clinical Lecturer in Medical Oncology with a clinical focus on the systemic management of patients with gynaecological malignancies. He also has a specialist clinical interest in cancer genetics and hereditary malignancies, particularly those involving the BRCA gene and other genetic mutations. He qualified in medicine at Leeds University Medical School, where he also gained a first class honours degree in Pharmacology. After completion of junior doctor posts at St. James’ Hospital in Leeds and Guys and St. Thomas’ Hospitals in London, he undertook his training in oncology at Charing Cross and Hammersmith Hospitals in London.
Dr Krell’s PhD research was funded by the Medical Research Council and investigated the interplay between genetic mutations, DNA damage and the response to cancer therapeutics. His ongoing research programme focuses on cancer genetics, polygenic risk and the interface between germline and somatic mutations, especially related to TP53 and BRCA. He also has a strong interest in the role of tumour and circulating small non-coding RNAs as diagnostic, prognostic and predictive biomarkers and as therapeutic modalities. This focuses on the areas of gynaecological and pancreatic malignancies and there is a strong translational research element to his work. He is a prominent member of the translational research team within the Ovarian Cancer Action Centre and Cancer Research UK centre at Imperial College that aims to overcome resistance to current anti-cancer agents in ovarian cancer. Current investigator-led trials include the OCA-funded PROGRESS study that aims to determine the feasibility of using a cancer risk algorithm to guide the personalisation of cancer screening and prevention programmes, and a BRC funded collaborative trial with the ICR investigating the role of Mainstreaming genetic testing in the cancer clinic.
Dr Krell has published over 100 peer-reviewed papers in journals such as the Lancet Oncology, Genome Research, The Journal of Clinical Oncology and Blood and regularly presents new data from his research at major national and international conferences.
Publications
Journals
Fuller-Shavel N, Krell J, 2024, Integrative Oncology Approaches to Supporting Immune Checkpoint Inhibitor Treatment of Solid Tumours., Curr Oncol Rep, Vol:26, Pages:164-174
Harris BHL, Mccabe C, Shafique H, et al., 2024, Diversity of thought: public perceptions of genetic testing across ethnic groups in the UK, Journal of Human Genetics, Vol:69, ISSN:1434-5161, Pages:19-25
Mato Prado M, Puik JR, Castellano L, et al., 2023, A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease, Experimental Hematology & Oncology, Vol:12, ISSN:2162-3619
Merali N, Chouari T, Terroire J, et al., 2023, Bile microbiome signatures associated with pancreatic ductal adenocarcinoma compared to benign disease: a UK pilot study, International Journal of Molecular Sciences, Vol:24, ISSN:1422-0067
Han SN, Oza A, Colombo N, et al., 2023, A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer., Gynecol Oncol, Vol:178, Pages:110-118